<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34268454</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-9238</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Endocrinology, diabetes &amp; metabolism</Title><ISOAbbreviation>Endocrinol Diabetes Metab</ISOAbbreviation></Journal><ArticleTitle>Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>e00246</StartPage><MedlinePgn>e00246</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00246</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/edm2.246</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The coronavirus disease 2019 (COVID-19) is currently a major pandemic challenge, and cancer patients are at a heightened risk of severity and mortality from this infection. In recent years, immune checkpoint inhibitor (ICI) use to treat multiple cancers has increased in oncology, but equally has raised the question of whether ICI therapy and its side-effects is harmful or beneficial during this pandemic.</AbstractText><AbstractText Label="METHODS">A combination of published literature in PubMed between January 2010 and December 2020, recommended guidelines in non-cancer patients, and clinical experience was utilized to outline recommendations on glucocorticoid timing and dosing regimens in ICI-treated patients presenting with AI during this COVID-19 pandemic.</AbstractText><AbstractText Label="RESULTS">The potential immune interaction between ICIs and COVID-19 require major consideration because these agents act at the intersection between effective cancer immunotherapy and increasing patient susceptibility, severity and complications from the SARS-CoV-2 sepsis. Furthermore, ICI use can induce autoimmune adrenal insufficiency (AI) that further increases infection susceptibility. Thus, ICI-treated cancer patients with AI may be at greater risk of COVID-19 infection. Glucocorticoids are the cornerstone for replacement therapy, and for treatment and mitigation of adrenal crisis and relief of mass effects in ICI-related hypophysitis. High-dose glucocorticoids have also been used with cytotoxic chemotherapy as part of cancer treatment, and iatrogenic AI may arise after glucocorticoid discontinuation that increases the risk of adrenal crisis. Furthermore, in patients who develop the "long COVID-19" syndrome, when to discontinue glucocorticoid therapy becomes crucial to avoid unnecessary prolongation of therapy and the development of iatrogenic hypercortisolemia.</AbstractText><AbstractText Label="CONCLUSION">During the COVID-19 pandemic, much of cancer care have been impacted and an important clinical question is how to optimally manage ICI-related AI during these unprecedented times. Herein, we suggest practical recommendations on the timing and dosing regimens of glucocorticoids in different clinical scenarios of ICI-treated cancer patients presenting with AI during this COVID-19 pandemic.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Endocrinology, Diabetes &amp; Metabolism published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Kevin C J</ForeName><Initials>KCJ</Initials><Identifier Source="ORCID">0000-0002-8169-2728</Identifier><AffiliationInfo><Affiliation>Departments of Neuroendocrinology and Neurosurgery Barrow Neurological Institute University of Arizona College of Medicine and Creighton School of Medicine Phoenix Arizona USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortensen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>University of Arizona College of Medicine-Phoenix Phoenix Arizona USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azadi</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neuro-Oncology Barrow Neurological Institute/Ivy Brain Center at Phoenix St. Joseph's Hospital and Medical Center Phoenix Arizona USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonkem</LastName><ForeName>Ekokobe</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neuro-Oncology Barrow Neurological Institute/Ivy Brain Center at Phoenix St. Joseph's Hospital and Medical Center Phoenix Arizona USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>James W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Molecular Medicine Medical College of Wisconsin Milwaukee Wisconsin USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Endocrinol Diabetes Metab</MedlineTA><NlmUniqueID>101732442</NlmUniqueID><ISSNLinking>2398-9238</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000309" MajorTopicYN="N">Adrenal Insufficiency</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">adrenal insufficiency</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">glucocorticoids</Keyword><Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword></KeywordList><CoiStatement>KCJY, MJM, AA, EF and JWF have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34268454</ArticleId><ArticleId IdType="pmc">PMC8250331</ArticleId><ArticleId IdType="doi">10.1002/edm2.246</ArticleId><ArticleId IdType="pii">EDM2246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92:401&#x2010;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166628</ArticleId><ArticleId IdType="pubmed">31950516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS&#x2010;CoV&#x2010;2: a multicenter study during the COVID&#x2010;19 outbreak. Cancer Discov. 2020;10:783&#x2010;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID&#x2010;19? An experience in New York City. Ann Oncol. 2020;31:1088&#x2010;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172785</ArticleId><ArticleId IdType="pubmed">32330541</ArticleId></ArticleIdList></Reference><Reference><Citation>Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID&#x2010;19 disease severity in patients with cancer. Nat Med. 2020;26:1218&#x2010;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785283</ArticleId><ArticleId IdType="pubmed">32581323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350&#x2010;1355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391259</ArticleId><ArticleId IdType="pubmed">29567705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly PN. The cancer immunotherapy revolution. Science. 2018;359:1344&#x2010;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">29567702</ArticleId></ArticleIdList></Reference><Reference><Citation>De Velasco G, Je Y, Bosse D, et al. Comprehensive meta&#x2010;analysis of key immune&#x2010;related adverse events from CTLA&#x2010;4 and PD&#x2010;1/PD&#x2010;L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5:312&#x2010;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5418853</ArticleId><ArticleId IdType="pubmed">28246107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252&#x2010;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856023</ArticleId><ArticleId IdType="pubmed">22437870</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID&#x2010;19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Honjo O, Kubo T, Sugaya F, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019;7:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448268</ArticleId><ArticleId IdType="pubmed">30944043</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C. A decade of immune&#x2010;checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7393098</ArticleId><ArticleId IdType="pubmed">32732879</ArticleId></ArticleIdList></Reference><Reference><Citation>Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with synthetic glucocorticoids and the hypothalamus&#x2010;pituitary&#x2010;adrenal axis. Int J Mol Sci. 2017;18:2201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666882</ArticleId><ArticleId IdType="pubmed">29053578</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal K, Yousaf N, Morganstein D. Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clin Med (Lond). 2020;20:163&#x2010;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081795</ArticleId><ArticleId IdType="pubmed">32188652</ArticleId></ArticleIdList></Reference><Reference><Citation>Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review. Crit Rev Oncol Hematol. 2017;120:86&#x2010;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">29198341</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zheng X, Huang Y, Shan H, Huang J. Successful use of methylprednisolone for treating severe COVID&#x2010;19. J Allergy Clin Immunol. 2020;146:325&#x2010;327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256545</ArticleId><ArticleId IdType="pubmed">32479759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator&#x2010;free in patients with moderate or severe acute respiratory distress syndrome and COVID&#x2010;19. JAMA. 2020;324(13):1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferra&#xf9; F, Ceccato F, Cannav&#xf2; S, Scaroni C. What we have to know about corticosteroids use during Sars&#x2010;Cov&#x2010;2 infection. J Endocrinol Invest. 2020:1&#x2010;9. 10.1007/s40618-020-01384-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01384-5</ArticleId><ArticleId IdType="pmc">PMC7454136</ArticleId><ArticleId IdType="pubmed">32860209</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, Arnaldi G, Boscaro M, et al. Italian Society of E. Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. J Endocrinol Invest. 2020;43:683&#x2010;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">31773582</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, Pofi R, Hasenmajer V, Lenzi A, Pivonello R. Use of glucocorticoids in patients with adrenal insufficiency and COVID&#x2010;19 infection. Lancet Diabetes Endocrinol. 2020;8:472&#x2010;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180011</ArticleId><ArticleId IdType="pubmed">32334645</ArticleId></ArticleIdList></Reference><Reference><Citation>Segelov E, Underhill C, Prenen H, et al. Practical considerations for treating patients with cancer in the COVID&#x2010;19 pandemic. JCO Oncol Pract. 2020;16:467&#x2010;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">32401686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115&#x2010;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">26808342</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder G, Rezza G, Brusaferro S. Case&#x2010;fatality rate and characteristics of patients dying in relation to COVID&#x2010;19 in Italy. JAMA. 2020;323(18):1775&#x2010;1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, et al. Cancer patients in SARS&#x2010;CoV&#x2010;2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335&#x2010;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Zhang L. Risk of COVID&#x2010;19 for patients with cancer. Lancet Oncol. 2020;21:e181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129735</ArticleId><ArticleId IdType="pubmed">32142621</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi SM, Liu VX. From containment to mitigation of COVID&#x2010;19 in the US. JAMA. 2020;323(15):1441&#x2010;1442.</Citation><ArticleIdList><ArticleId IdType="pubmed">32167525</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LS, Barroso&#x2010;Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40:17&#x2010;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6270990</ArticleId><ArticleId IdType="pubmed">30184160</ArticleId></ArticleIdList></Reference><Reference><Citation>Min L, Hodi FS, Giobbie&#x2010;Hurder A, et al. Systemic high&#x2010;dose corticosteroid treatment does not improve the outcome of ipilimumab&#x2010;related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21:749&#x2010;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334697</ArticleId><ArticleId IdType="pubmed">25538262</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019&#x2010;nCoV lung injury. Lancet. 2020;395:473&#x2010;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7134694</ArticleId><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Castillo M, Romero FA, Arguello E, Kyi C, Postow MA, Redelman&#x2010;Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63:1490&#x2010;1493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5106605</ArticleId><ArticleId IdType="pubmed">27501841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassi E, Angelousi A, Asonitis N, et al. Endocrine&#x2010;related adverse events associated with immune&#x2010;checkpoint inhibitors in patients with melanoma. Cancer Med. 2019;8:6585&#x2010;6594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6825974</ArticleId><ArticleId IdType="pubmed">31518074</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697162</ArticleId><ArticleId IdType="pubmed">29162153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanie K, Iguchi G, Bando H, et al. Two cases of atezolizumab&#x2010;induced hypophysitis. J Endocr Soc. 2018;2:91&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774896</ArticleId><ArticleId IdType="pubmed">29362727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi I, Brancatella A, Cosottini M, et al. Clinical heterogeneity of hypophysitis secondary to PD&#x2010;1/PD&#x2010;L1 blockade: insights from four cases. Endocrinol Diabetes Metab Case Rep. 2019;2019:19&#x2010;0102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790893</ArticleId><ArticleId IdType="pubmed">31610523</ArticleId></ArticleIdList></Reference><Reference><Citation>Percik R, Shlomai G, Tirosh A, et al. Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmun Rev. 2020;19:102454.</Citation><ArticleIdList><ArticleId IdType="pubmed">31838158</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelmachowska&#x2010;Banas M, Czajka&#x2010;Oraniec I. Management of endocrine immune&#x2010;related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect. 2020;9:R207&#x2010;R228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7576644</ArticleId><ArticleId IdType="pubmed">33064663</ArticleId></ArticleIdList></Reference><Reference><Citation>Carril&#x2010;Ajuria L, Jimenez&#x2010;Aguilar E, Gomez&#x2010;Martin C, Diaz&#x2010;Pedroche C. An unsuspected complication with immune checkpoint blockade: a case report. J Med Case Rep. 2018;12:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6122676</ArticleId><ArticleId IdType="pubmed">30176934</ArticleId></ArticleIdList></Reference><Reference><Citation>Caturegli P, Lupi I, Landek&#x2010;Salgado M, Kimura H, Rose NR. Pituitary autoimmunity: 30 years later. Autoimmun Rev. 2008;7:631&#x2010;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383826</ArticleId><ArticleId IdType="pubmed">18774118</ArticleId></ArticleIdList></Reference><Reference><Citation>Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev. 2005;26:599&#x2010;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">15634713</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013;98:1466&#x2010;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">23457412</ArticleId></ArticleIdList></Reference><Reference><Citation>Tresoldi AS, Sumilo D, Perrins M, et al. Increased infection risk in Addison's disease and congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2020;105:418&#x2010;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046014</ArticleId><ArticleId IdType="pubmed">31532828</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodro M, Gudiol C, Garcia&#x2010;Vidal C, et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug&#x2010;resistant ESKAPE pathogens in cancer patients. Support Care Cancer. 2014;22:603&#x2010;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">24170166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalaoui R, Javelle E, Bakour S, Ubeda C, Rolain JM. Infections due to carbapenem&#x2010;resistant bacteria in patients with hematologic malignancies. Front Microbiol. 2020;11:1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379235</ArticleId><ArticleId IdType="pubmed">32765433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103&#x2010;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">12715303</ArticleId></ArticleIdList></Reference><Reference><Citation>Postow MA. Managing immune checkpoint&#x2010;blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">25993145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbi S, Hannah&#x2010;Shmouni F, Verbalis JG, Koch CA. Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab. 2019;33:101371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078033</ArticleId><ArticleId IdType="pubmed">31866206</ArticleId></ArticleIdList></Reference><Reference><Citation>Grouthier V, Lebrun&#x2010;Vignes B, Moey M, et al. Immune checkpoint inhibitor&#x2010;associated primary adrenal insufficiency: WHO VigiBase report analysis. Oncologist. 2020;10:696&#x2010;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418341</ArticleId><ArticleId IdType="pubmed">32390168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R, Banerjee M. COVID&#x2010;19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43:1027&#x2010;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195612</ArticleId><ArticleId IdType="pubmed">32361826</ArticleId></ArticleIdList></Reference><Reference><Citation>Puar TH, Stikkelbroeck NM, Smans LC, Zelissen PM, Hermus AR. Adrenal crisis: still a deadly event in the 21st century. Am J Med. 2016;129(339):e331&#x2010;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">26363354</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes PJ. Anti&#x2010;inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94:557&#x2010;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854452</ArticleId></ArticleIdList></Reference><Reference><Citation>Pufall MA. Glucocorticoids and cancer. Adv Exp Med Biol. 2015;872:315&#x2010;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546099</ArticleId><ArticleId IdType="pubmed">26216001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutolo M, Seriolo B, Pizzorni C, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8:153&#x2010;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">18703175</ArticleId></ArticleIdList></Reference><Reference><Citation>Broersen LH, Pereira AM, Jorgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta&#x2010;analysis. J Clin Endocrinol Metab. 2015;100:2171&#x2010;2180.</Citation><ArticleIdList><ArticleId IdType="pubmed">25844620</ArticleId></ArticleIdList></Reference><Reference><Citation>Jairam V, Yang DX, Verma V, Yu JB, Park HS. National patterns in prescription opioid use and misuse among cancer survivors in the United States. JAMA Netw Open. 2020;3:e2013605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431994</ArticleId><ArticleId IdType="pubmed">32804217</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Cunningham JL, Gilliam WP, Loukianova L, Donegan DM, Bancos I. Prevalence of opioid&#x2010;induced adrenal insufficiency in patients taking chronic opioids. J Clin Endocrinol Metab. 2020;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470471</ArticleId><ArticleId IdType="pubmed">32866966</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med. 1989;321:492&#x2010;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">2548097</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:3888&#x2010;3921.</Citation><ArticleIdList><ArticleId IdType="pubmed">27736313</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rivero J, Cordes LM, Klubo&#x2010;Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL. Endocrine&#x2010;related adverse events related to immune checkpoint inhibitors: proposed algorithms for management. Oncologist. 2020;25:290&#x2010;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160393</ArticleId><ArticleId IdType="pubmed">32297436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari SM, Fallahi P, Elia G, et al. Autoimmune endocrine dysfunctions associated with cancer immunotherapies. Int J Mol Sci. 2019;20:2560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6566424</ArticleId><ArticleId IdType="pubmed">31137683</ArticleId></ArticleIdList></Reference><Reference><Citation>Javorsky B, Carroll T, Algeciras&#x2010;Schimnich A, Singh R, Colon&#x2010;Franco J, Findling J. SAT&#x2013;390 New cortisol threshold for diagnosis of adrenal insufficiency after cosyntropin stimulation testing using the Elecsys Cortisol II, Access Cortisol, and LC&#x2010;MS/MS assays. J Endocr Soc. 2019;3(Suppl:1):SAT&#x2010;390. 10.1210/js.2019-SAT-390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/js.2019-SAT-390</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MJ, Kitsis EA, Arora S, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID&#x2010;19. J Hosp Med. 2020;15:489&#x2010;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7518134</ArticleId><ArticleId IdType="pubmed">32804611</ArticleId></ArticleIdList></Reference><Reference><Citation>Solinas C, Perra L, Aiello M, Migliori E, Petrosillo N. A critical evaluation of glucocorticoids in the management of severe COVID&#x2010;19. Cytokine Growth Factor Rev. 2020;54:8&#x2010;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313507</ArticleId><ArticleId IdType="pubmed">32616381</ArticleId></ArticleIdList></Reference><Reference><Citation>Higham CE, Olsson&#x2010;Brown A, Carroll P, et al. Society for Endocrinology Clinical C. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7:G1&#x2010;G7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013692</ArticleId><ArticleId IdType="pubmed">29930025</ArticleId></ArticleIdList></Reference><Reference><Citation>Auyeung TW, Lee JS, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51:98&#x2010;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132384</ArticleId><ArticleId IdType="pubmed">16038758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS&#x2010;associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304&#x2010;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108318</ArticleId><ArticleId IdType="pubmed">15494274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury LE, Rodrigo C, Leonardi&#x2010;Bee J, Nguyen&#x2010;Van&#x2010;Tam J, Shen LW. Corticosteroids as adjunctive therapy in the treatment ofiInfluenza: an updated Cochrane systematic review and meta&#x2010;analysis. Crit Care Med. 2020;48:e98&#x2010;e106.</Citation><ArticleIdList><ArticleId IdType="pubmed">31939808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid&#x2010;19: Hydrocortisone can be used as alternative to dexamethasone, review finds. BMJ. 2020;370:m3472.</Citation><ArticleIdList><ArticleId IdType="pubmed">32887677</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin YY, Zhou YH, Lu YQ, et al. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial. Chin Med J (Engl). 2020;133:1080&#x2010;1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147272</ArticleId><ArticleId IdType="pubmed">32149773</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, Arnaldi G, Boscaro M, et al. COVID&#x2010;19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020;43:1141&#x2010;1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182741</ArticleId><ArticleId IdType="pubmed">32335855</ArticleId></ArticleIdList></Reference><Reference><Citation>Prete A, Taylor AE, Bancos I, et al. Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery. J Clin Endocrinol Metab. 2020;105(7):2262&#x2010;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241266</ArticleId><ArticleId IdType="pubmed">32170323</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson H, Tomlinson J, Wass J, Dean J, Arlt W. Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. Clin Med (Lond). 2020;20:371&#x2010;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385786</ArticleId><ArticleId IdType="pubmed">32675141</ArticleId></ArticleIdList></Reference><Reference><Citation>Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow&#x2010;up. Ann Oncol. 2017;28(Suppl 4):iv119&#x2010;iv142.</Citation><ArticleIdList><ArticleId IdType="pubmed">28881921</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID&#x2010;19 and its therapeutic implications. Circ Res. 2020;127:571&#x2010;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386875</ArticleId><ArticleId IdType="pubmed">32586214</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Isidori AM, De Martino MC, Newell&#x2010;Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4:611&#x2010;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">27177728</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol. 2015;173:R101&#x2010;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">25987566</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention
. Long&#x2010;term effects of COVID&#x2010;19. https://www.cdc.gov/coronavirus/2019&#x2010;ncov/long&#x2010;term&#x2010;effects.html. Accessed November 28, 2020.</Citation></Reference><Reference><Citation>Mishra GP, Mulani J. Corticosteroids for COVID&#x2010;19: the search for an optimum duration of therapy. Lancet Respi Med. 2020. Jan;9(1):e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836750</ArticleId><ArticleId IdType="pubmed">33248469</ArticleId></ArticleIdList></Reference><Reference><Citation>
The RECOVERY Collaboraive Group
. Dexamethasone in hospitalized patients with Covid&#x2010;19&#x2014;preliminary report. N Engl J Med. 2020; 9(1):e8. https://www.nejm.org/doi/full/10.1056/NEJMoa2021436: Accessed November 28, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with COVID&#x2010;19: addressing uncertainties. Lancet Respir Med. 2020;8(12):1170&#x2010;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598750</ArticleId><ArticleId IdType="pubmed">33129421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano EJ, Fonseca Fuentes X, Corsini Campioli C, et al. Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta&#x2010;analysis. Chest. 2020. Oct:S0012&#x2010;3692(20)35107&#x2010;2. 10.1016/j.chest.2020.10.054. Epub ahead of print. PMID: 33129791; PMCID: PMC7598533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.10.054</ArticleId><ArticleId IdType="pmc">PMC7598533</ArticleId><ArticleId IdType="pubmed">33129791</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>